Alnylam Pharmaceuticals Presents New Pre-Clinical Data With ALN-CC5, A Subcutaneously Administered Rnai Therapeutic Targeting Complement Component C5 In Development For The Treatment Of Complement-Mediated Diseases

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today new pre-clinical results with ALN-CC5, a subcutaneously administered RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases. These results were presented at the 25th International Complement Workshop being held September 14 – 18, 2014, in Rio de Janeiro, Brazil. Amongst other results, new positive data were reported from non-human primate (NHP) studies evaluating a monthly subcutaneous ALN-CC5 dose regimen, and from a rodent model of primary membranous nephropathy (MN) – a complement-mediated progressive disease of the kidney with high unmet need – where anti-C5 monoclonal antibody (mAb) therapy has demonstrated incomplete effectiveness (Cunningham et al., J Am Soc Nephrol 2005, 16:1214-1222). The company remains on track to file its ALN-CC5 Clinical Trial Application (CTA) in late 2014 and expects to present initial clinical results in mid-2015.

Help employers find you! Check out all the jobs and post your resume.